Fosun Pharma and Insilico Medicine joined for AI-driven discovery of four biological targets
Shanghai Fosun Pharmaceutical (Group) Co., Ltd a leading innovation-driven international healthcare group in China and Insilico Medicine an end-to-end artificial intelligence (AI)-driven drug discovery and development company, entered into a collaboration agreement to advance the discovery and development of drugs targeting a number of different targets globally through the use of AI technology.